Giant leap for MannKind's Affrezza as Colby takes immunotherapies off back burner
This article was originally published in Scrip
Executive Summary
MannKind stands to gain up to $140 million in upfront and milestone payments plus royalties under a license agreement with Colby Pharmaceutical, which will take over development of novel MKC1106 immunotherapies, allowing MannKind to move another oncology asset forward while remaining focused on Phase III development of its inhaled diabetes drug Affrezza.